Heidelberg

Düsseldorf

Hamburg

Dresden

Magdeburg

München

about MENINGIOMA consortium

The Con­sor­tium is com­prised of 4 DKFZ sites and 5 Inter­dis­ci­pli­nary Oncol­o­gy Cen­ters of Excel­lence, with 17 researchers in the areas of Neu­ro­surgery, Neu­ron­col­o­gy, Neu­ropathol­o­gy Tumor Biol­o­gy, Engi­neer­ing, and Bio-infor­mat­ics. The Con­sor­tium focus­es on three pillars:

  • The first is the devel­op­ment of nov­el tests (bio­mark­ers) to reli­ably iden­ti­fy which menin­giomas will behave aggres­sive­ly and which will not.
  • The sec­ond is the devel­op­ment of cell mod­els that allow for the study of the bio­log­i­cal mech­a­nisms respon­si­ble for the aggres­sive behav­ior of menin­gioma cells.
  • The third is the devel­op­ment of nov­el ther­a­peu­tic approach­es based on a more pro­found char­ac­ter­i­za­tion of these tumors and tumor-spe­cif­ic aberrations.